Cryoviva (Thailand) Ltd., a stem cell bank that includes a cell expansion facility in its network, launches its “World Class” laboratory, tripling from it’s original facility size, to meet the production needs of “medicinal products” in the ATMP category, adhering to GMP/PICS standards, capable of producing up to 500 billion cells per year.
Cryoviva has experienced significant growth in all sectors, becoming a global player and Thailand’s leader in stem cell innovation, offering top quality stem cells through superior laboratory standards and processes, advanced technology, expert technical teams, and an expansive network of partners. Tripling its lab capacity, Cryoviva aims to be Asia’s largest producer, expanding stem cell storage opportunities from newborns to the public under the slogan “Cryoviva supports everyone to have a better quality of life with stem cells.”
For the first time in Thailand, Cryoviva as the pioneer has developed, improved, and modified its stem cell bank operations to comply with new ATMP (Advanced Therapy Medicinal Product) standards, aligned with GMP/PICS standards as per European Union guidelines for advanced medicinal product production, focusing on risk prevention and elimination to ensure safety.
Cryoviva (Thailand) Co., Ltd. will announce its nearly two decades of successful operations, led by Ms. Chiranya Prachaseri, Chief Executive Officer of Southeast Asia, alongside executives, medical teams, and honored guests from the medical and academic sectors. They will provide insights into the increasingly recognized benefits of stem cell technology, featuring Cryoviva’s brand ambassadors “New Napassorn Suwananon and Peck Premmanat Suwananon.”
Stem cells, a natural gift from birth, are predicted to play an increasing role in treating and restoring health for the individual and their loved ones. Cryoviva was established 17 years ago to preserve this gift for sustainable health, offering a modern health care option for present and future needs.
Establishment of Cryoviva for Health’s Future
Cryoviva was founded in 2007 through a collaborative vision for the future of health by leading global companies and the support of Mrs. Suchitra and Mr. Aloke Lohia and Mrs. Dhara and Mr. Ravi Jaipuria.
With extensive experience and visionary leadership, Ms. Chiranya Prachaseri, CEO of Southeast Asia, has propelled Cryoviva to become Thailand’s best and most secure stem cell storage and cultivation facility. Supported by a qualified management team, , medical experts, and scientists specialized in stem cells, as well as local and international hematology and cell therapy specialists, Cryoviva is dedicated to continuous improvement, quality, safety and ethical operations.
“The most important aspect for us is our expert staff who prioritize quality over all else. Over the past 17 years, the number of families entrusting Cryoviva to store their stem cells has grown exponentially, reflecting their trust in our quality. Our partnerships with medical professionals, clinics, and hospitals where we collect and use stem cells for necessary treatments, bring us great pride,” said Ms. Chiranya.
Ms. Chiranya further revealed future plans, emphasizing on the increase of qualified personnel and expansion of partnerships with healthcare facilities in the region to collaborations with government, academic, and scientific institutions to increase the awareness of the potential of stem cells in health and wellness and future and make standard therapies more accessible to the public.
Statistically, Thailand ranks second in Asia for its aging population. Cryoviva aims to enhance the health and quality of life for the elderly by making treatments affordable. Another goal is to engage in clinical trials and develop standard medical treatments which will be made available to the public, potentially reducing national healthcare costs. With Thailand having top-tier medical professionals in stem cell research, Cryoviva is confident in achieving these goals soon.
Ms. Chiranya states that “Cryoviva’s state of the art laboratory will be continuously developed and the company hopes to serve as a model for the industry. In addition, expansion in the region is a key objective.” She believes that if both private and public sectors drive this business seriously, stem cell therapy will benefit not only benefit the medical and health and wellness industries, but also generate significant economic gains, given Thailand’s globally recognized medical services and thriving medical tourism industry.
Stem Cells: A Gift for Health
Stem cells, are remarkable for their ability to divide and transform into various tissue cells, such as skin, brain, heart, muscle, and blood cells, replacing deteriorated cells. Cryoviva focuses on good health and quality of life for everyone, as stem cells can be collected from all individuals.
Stem cells are considered the future of healthcare, offering numerous benefits for the health of children and family members. Umbilical cord blood stem cells can treat over 85 diseases, including blood cancers, anemia, thalassemia, bone marrow disorders, immune deficiencies, red blood cell abnormalities, and metabolic disorders.
Clinical trials that have been conducted in a number of countries for numerous health conidtions show great hope for the future. Umbilical cord tissue stem cells have shown to improve the quality of life of patients with Alzheimer’s, muscle weakness, bone and joint diseases, and can enhance beauty by reducing wrinkles and combat hair loss. Placental tissue stem cells have also shown positive results in the treatment of neurological disorders suc as Parkinson’s, stroke, autism, and other degenerative diseases. Fat-derived stem cells, apart from aesthetic uses, can rejuvenate bone and joint diseases and autoimmune disorders. Importantly, fat-derived stem cells can be collected from adults, not just newborns.
Combining these aspects, Cryoviva has solidified its position as a leader in stem cell innovation. The rapid increase in organizational trust has led to significant advancements in medical stem cell laboratories in Thailand, expanding to a “World Class” lab, tripled in size, to meet the production needs of ATMP products, adhering to GMP/PICS standards, capable of producing 500 billion cells per year.
“Elevating Global Lab Standards and Production Capacity for the Future.”
For the first time in Thailand, Cryoviva has developed, improved, and modified its stem cell bank operations to comply with new ATMP (Advanced Therapy Medicinal Product) standards, aligned with GMP/PICS standards as per European Union guidelines for advanced medicinal product production, focusing on risk prevention and elimination to ensure safety. Cryoviva is one of only three stem cell banks in Southeast Asia accredited by the AABB (Association for the Advancement of Blood & Biotherapies) in both stem cell storage and cultivation.
Exponential Growth
Cryoviva has experienced a compound annual growth rate of 38%, ranking among the world’s top 10, with an MSCs (Mesenchymal Stem Cells) production capacity of up to 500 billion cells per year for Cryoviva families. Cryoviva has expanded its robust network to provide services across five continents, including America, Europe, Africa, Australia, and Asia, covering over 20 countries, with four AABB-accredited labs in Thailand, Singapore, Vietnam, and India.
“We know that stem cell innovation can improve life quality, and we are committed to bringing you the best. Cryoviva brings success, moves into the future, and elevates innovation collaboration for quality life.”
**For more information, please contact:**
Phone: 02 203 6982, 094 449 9445
Facebook: [Cryoviva]
Website: [Cryoviva]
